Henrietta, United States
OYAGEN INC. is a biotechnology company founded in 2003 with the goal of discovering, developing, and commercializing novel pharmaceutical therapies that exploit RNA editing and DNA editing enzymes. It holds exclusive rights to technologies from University of Rochester Medical Center (URMC), Thomas Jefferson University (TJU), and Oregon Health Science Center.
The company's focus is on harnessing the editing process to create therapies for various disease states, particularly in the treatment of Human Immunodeficiency Virus (HIV). OyaGen has identified an Editing Enzyme present in the immune system and has determined its significance in the HIV infection cycle. This has led to the development of strategies to halt HIV by allowing this Editing Enzyme to function.
In terms of development, OyaGen is pursuing proprietary assays in high throughput screening strategies for drug development. Specifically, it aims to bring to market anti-HIV drugs targeting Vif and APOBEC3G to address viral resistance, a major shortcoming of current therapies. Additionally, the company plans to leverage its expertise in Editing Enzyme technologies to develop therapies for other disease states.
OyaGen also offers method development and testing as a fee-for-service, along with expert consulting services in various areas related to high throughput drug discovery, drug development, and preparing federal grants.
The company received a $150.00K grant investment on 16 September 2013 from the New York State Common Retirement Fund.
